Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (ADAPT-PO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03788967
Recruitment Status : Recruiting
First Posted : December 28, 2018
Last Update Posted : November 1, 2019
Sponsor:
Information provided by (Responsible Party):
Spero Therapeutics

Brief Summary:
The key purpose of this study is to evaluate the efficacy, safety and pharmacokinetics (PK) of TBPM-PI-HBr compared to IV ertapenem, in subjects with Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP).

Condition or disease Intervention/treatment Phase
Complicated Urinary Tract Infection Acute Pyelonephritis Drug: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Drug: Ertapenem Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Actual Study Start Date : June 3, 2019
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : June 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: TBPM-PI-HBr 300 mg film-coated tablets
TBPM-PI-HBr 600 mg administered orally three times per day for 7 to 10 days.
Drug: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
Antibiotic Therapy for Complicated Urinary Tract Infection
Other Name: SPR994

Active Comparator: Ertapenem
Ertapenem for IV injection administered as a 1-gram IV infusion over 30 min once daily for 7 to 10 days.
Drug: Ertapenem
Antibiotic Therapy for Complicated Urinary Tract Infection




Primary Outcome Measures :
  1. Number of patients with overall response (combined clinical cure plus microbiological eradication) at test-of-cure (TOC) in the micro- intent-to-treat (ITT) population [ Time Frame: Day 19 +/- 2 days ]

    Clinical cure is defined as complete resolution or significant improvement of signs and symptoms of cUTI or AP that were present at baseline and no new symptoms, such that no further antimicrobial therapy is warranted.

    Microbiological eradication is defined as reduction of baseline urine pathogen(s) to <10^3 colony forming unit/milliliter (CFU/mL) and negative repeated blood culture if blood culture was positive for uropathogen growth at baseline.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Male and female subjects at least 18 years of age
  2. Able to provide informed consent
  3. Able to ingest oral tablets for the anticipated treatment duration
  4. Have a diagnosis of cUTI or AP as defined below:

    a. cUTI definition:

    At least Two of the following signs and symptoms:

    i. Chills, rigors, or fever; fever must be observed and documented by a health care provider (oral, tympanic, rectal or core temperature >38.0°C [>100.4°F])

    ii. Dysuria, urgency to void, or increased urinary frequency

    iii. Nausea or vomiting, as reported by the subject

    iv. Lower abdominal, suprapubic, or pelvic pain

    And at least One of the following risk factors for cUTI:

    i. Implanted urinary tract instrumentation (e.g., nephrostomy tube, ureteric stents, or other urinary tract prosthetic material), ongoing intermittent bladder catheterization, or presence of an indwelling bladder catheter (Note: bladder catheters that have been in place for >24 hours prior to Screening must be removed or replaced prior to collection of the Screening urine for urinalysis and culture, unless removal or replacement is considered unsafe or contraindicated)

    ii. Current known functional or anatomical abnormality of the urogenital tract, including anatomic abnormalities of the urinary tract, neurogenic bladder, or post-void residual urine volume of ≥ 100 mL within the past 6 months

    iii. Complete or partial obstructive uropathy (e.g., nephrolithiasis, tumor, fibrosis, urethral stricture) that is expected to be medically or surgically treated during study drug therapy (prior to EOT)

    iv. Known intrinsic renal disease with blood urea nitrogen (BUN) >20 mg/deciliter (dL), or blood urea >42.8 mg/dL, or serum creatinine (Cr) >1.4 mg/dL

    v. Urinary retention, including urinary retention in men due to previously diagnosed benign prostatic hyperplasia (BPH)

    b. AP definition: Acute flank pain (onset within 7 days prior to randomization) or costovertebral angle tenderness on physical examination.

    And at least One of the following signs and symptoms:

    i. Chills, rigors, or fever; fever must be observed and documented by a health care provider (oral, tympanic, rectal or core temperature >38.0°C [>100.4°F])

    ii. Peripheral white blood cell count (WBC) >10,000/mm3 or bandemia (≥15% immature polymorphonuclear neutrophils (PMNs), regardless of WBC count)

    iii. Nausea or vomiting, as reported by the subject

    iv. Dysuria, urgency to void, or increased urinary frequency

    Note: Subjects who meet the definition for cUTI (Inclusion Criterion 4a) and also have flank pain or costovertebral tenderness should be randomized as cUTI rather than AP.

  5. Have an adequate urine specimen for evaluation and culture obtained within 24 h prior to randomization with evidence of pyuria that includes at least one of the following:

    1. At least 10 WBCs per high power field (hpf) in urine sediment
    2. At least 10 WBCs per cubic millimeter (mm3) in unspun (non centrifuged) urine
    3. Positive leukocyte esterase (LE) on urinalysis

    Note: Subjects may be randomized and administered investigational product (IP) prior to knowledge of urine culture results.

  6. Expectation, in the judgment of the Investigator, that the subject will survive with effective antibiotic therapy and appropriate supportive care for the anticipated duration of the study
  7. Willing to comply with all the study activities and procedures throughout the duration of the study
  8. Subjects must agree to use a highly-effective method of birth control; male subjects must agree to use an effective barrier method of contraception from Screening through late follow-up (LFU) and for 90 days following the last dose if sexually active with a female of childbearing potential (FOCP); female subjects must not be pregnant or nursing, and must commit to either sexual abstinence or use at least two medically accepted, effective methods of birth control (e.g., condom, spermicidal gel, oral contraceptive, indwelling intrauterine device, hormonal implant/patch, injections, approved cervical ring) from Screening through LFU and for 90 days following the last dose.

Exclusion Criteria

  1. Presence of any known or suspected disease or condition that, in the opinion of the Investigator, may confound the assessment of efficacy, including but not limited to the following:

    1. Perinephric or renal corticomedullary abscess
    2. Uncomplicated urinary tract infection (uUTI) - (acute cystitis that does not meet the cUTI disease definition, see Inclusion Criterion 4a)
    3. Polycystic kidney disease
    4. Recent history of trauma to the pelvis or urinary tract
    5. Confirmed or suspected acute or chronic bacterial prostatitis, orchitis, or epididymitis
    6. Chronic vesicoureteral reflux
    7. Previous or planned renal transplantation
    8. Previous or planned cystectomy or ileal loop surgery
    9. Known or suspected non-renal source of infection (e.g., infective endocarditis, osteomyelitis, meningitis, pneumonia)
    10. Confirmed or suspected infection that is caused by a pathogen that is resistant to either IP (e.g., carbapenem-resistant pathogen), including infection caused by fungi (e.g., candiduria) or mycobacteria (e.g., urogenital tuberculosis)
  2. Gross hematuria requiring intervention other than administration of IP or removal/placement of urinary tract instrumentation
  3. Urinary tract surgery within 7 days prior to randomization or urinary tract surgery planned during the study period (except surgery required relieving an obstruction or placing urinary tract instrumentation)
  4. Creatinine clearance (CrCl) of <50 mL/min, as estimated by the Cockcroft-Gault formula:

    estimated Creatinine Clearance (eC_Cr) [mL/min]=((140-Age [yrs]) × Body Weight [kg] × [0.85 if Female])/(72 × Serum Creatinine [mg⁄dL])

  5. Anticipated concomitant use of non-study antibacterial drug therapy between randomization and the LFU Visit that would potentially effect outcome evaluations of cUTI/ AP, including but not limited to antibacterials with potential activity versus uropathogens, antibacterial drug prophylaxis, and antibacterial bladder irrigation
  6. Anticipated concomitant use of gastric acid-reducing medications between randomization and end-of-treatment (EOT), including proton pump inhibitors, histamine-2 receptor antagonists, and antacids
  7. Receipt of more than a single dose of a short-acting potentially effective antibiotic within 72 h prior to randomization; no more than 25% of subjects will be enrolled who meet the above criterion

    Exception: Subjects who received more than a single dose of short-acting potentially effective antibiotic within 72 h prior to randomization may be eligible for enrollment if they meet all of the following criteria:

    1. In the opinion of the Investigator they have failed the prior antibiotic therapy (e.g., have worsening signs and symptoms of cUTI/AP)
    2. Have a documented uropathogen (growth in urine culture >105 CFU/mL) that is resistant to the prior antibiotic therapy
    3. Have a documented uropathogen that is carbapenem-susceptible
    4. Receives approval from the Medical Monitor to enroll the subject
  8. Severe hepatic impairment at Screening, as evidenced by alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >5x upper limit of normal (ULN) or total bilirubin >3x ULN, or clinical signs of cirrhosis or end-stage hepatic disease (e.g., ascites, hepatic encephalopathy)
  9. Any signs of severe sepsis, including shock or profound hypotension defined as systolic blood pressure <90 mmHg or a decrease of >40 mmHg from baseline that is not responsive to fluid challenge
  10. Pregnant or breastfeeding women
  11. History of epilepsy or known seizure disorder (excluding a history of childhood febrile seizures)
  12. Receipt of any investigational medication during the last 30 days or 5 half-lives, whichever is longer, prior to randomization
  13. Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-defining illness, or known cluster of differentiation 4 (CD4) count <200/mm3 within the past year
  14. Presence of immunodeficiency or an immunocompromised condition including neutropenia (<1,000 neutrophils/mm3 obtained from the local laboratory at Screening), hematologic malignancy, bone marrow transplant, or receiving immunosuppressive therapy such as cancer chemotherapy, medications for the rejection of transplantation, and long term use of systemic corticosteroids (e.g., ≥20 mg/day of prednisone or systemic equivalent for at least 2 weeks)
  15. A mean QT interval corrected using Fridericia's formula (QTcF) >480 msec based on triplicate ECGs at Screening
  16. History of significant hypersensitivity or allergic reaction to β-lactam antibiotics (e.g., cephalosporins, penicillins, carbapenems), product excipients (Mannitol, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and Opadry) or any contraindication to the use of ertapenem
  17. History of known genetic metabolism anomaly associated with carnitine deficiency (e.g., carnitine transporter defect, methylmalonic aciduria, propionic acidemia)
  18. Requirement for concomitant use of valproic acid, divalproex sodium, or probenecid between randomization and EOT
  19. Unable or unwilling to comply with the protocol
  20. An employee of the Investigator or study center with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as a family member of the employee or the Investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03788967


Contacts
Layout table for location contacts
Contact: Hanna Kwak +1-857-242-1568 Hkwak@sperotherapeutics.com
Contact: Tim Keutzer +1-857-242-1600 tim@sperotherapeutics.com

  Show 56 Study Locations
Sponsors and Collaborators
Spero Therapeutics
Investigators
Layout table for investigator information
Study Director: David Melnick, MD Spero Therapeutics, Inc.

Layout table for additonal information
Responsible Party: Spero Therapeutics
ClinicalTrials.gov Identifier: NCT03788967     History of Changes
Other Study ID Numbers: SPR994-301
First Posted: December 28, 2018    Key Record Dates
Last Update Posted: November 1, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Spero Therapeutics:
Complicated Urinary Tract Infection
Acute Pyelonephritis
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Urinary Tract Infections
Pyelonephritis
Urologic Diseases
Nephritis, Interstitial
Nephritis
Kidney Diseases
Pyelitis
Ertapenem
Anti-Bacterial Agents
Anti-Infective Agents